Pharma News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • PAREXEL International Corporation, a global clinical research organization, announced today that the Company has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a leading provider of specialized pharmacovigilance services, based in Chandigarh, India.  Pharmacovigilance refers to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products.  The acquisition is expected to close in early April of 2015, subject to the satisfaction of closing conditions.

  • Novo Nordisk today announced the company will launch Novoeight® (Antihemophilic Factor [Recombinant]) in the United States for people living with hemophilia A. Novoeight® offers purity, reliability, and enhanced portability, with the highest storage temperature for the longest period of time compared with other marketed recombinant Factor VIII products—up to 86 degrees F for 12 months. It can be kept at that temperature for up to 4 hours after reconstitution, giving it the longest postreconstitution storage time. Novoeight® offers purity through a 5-step purification process. It was shown to be safe and effective in clinical trials with zero inhibitors confirmed in 213 previously treated patients with hemophilia A. Novo Nordisk plans to make Novoeight® available by mid-April 2015.

  • According to a new market research report "Tumor Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation Market is expected to reach around $462.0 Million growing at a CAGR of 11.50% by 2019.

  • Sun Pharmaceutical Industries Ltd.  begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.

  • Dr. Reddy’s Custom Pharmaceutical Services (CPS) division has expanded its existing custom service facilities with a new formulation development laboratory in Miyapur, Hyderabad, India. Bringing together the existing API development team and the formulation teams at one location will accelerate project timelines, reduce costs and simplify licensing processes for CPS’ pharma customers.

  • World Health Organization (WHO) Country office for India in collaboration with the Ministry of Health and Family Welfare, Government of India and National Health Systems Resource Centre (NHSRC), formally announced the commencement of National Health Systems Resource Centre (NHSRC), as the WHO Collaborating Centre for Priority Medical Devices and Health Technology Policy.

  • Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients.

    [adsense:336x280:8701650588]

  • Scientists have discovered the hiding place of HIV in cells, an advance that may lead to new therapies to combat the deadly virus. Researchers at the International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy have photographed the structure of nucleic lymphocytes with a high-resolution microscopy technique to discover the "hiding place" of HIV.

  • Scientists have identified the first-ever evidence of a human population uniquely adapted to tolerate the toxic chemical arsenic in the Andes Mountains of Argentina. A Swedish research team led by Karolinska Institutet and Uppsala University professor Karin Broberg, performed a genome wide survey from a group of 124 Andean women screened for the ability to metabolise arsenic (measured by levels in the urine).

  • Scientists have for the first time found that an abnormal protein whose accumulation in the brain is a hallmark of Alzheimer's disease starts building up inside neurons of people as young as 20. It has long been known that amyloid accumulates and forms clumps of plaque outside neurons in ageing adults and in Alzheimer's but this is the first time amyloid accumulation has been shown in such young human brains, researchers said.

Subscribe to Pharma News